These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 862650)

  • 21. Short-term tolbutamide effect on patients with liver cirrhosis.
    Hirayama C; Kawasaki H; Arimura K; Amagase H
    Acta Hepatogastroenterol (Stuttg); 1974 Feb; 21(1):34-40. PubMed ID: 4450960
    [No Abstract]   [Full Text] [Related]  

  • 22. Influence of rifampicin treatment on antipyrine clearance and metabolite formation in patients with tuberculosis.
    Teunissen MW; Bakker W; Meerburg-Van der Torren JE; Breimer DD
    Br J Clin Pharmacol; 1984 Nov; 18(5):701-6. PubMed ID: 6508979
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Drug metabolism in patients with liver disease (author's transl)].
    Richter E; Epping J; Fuchshofen-Röckel M; Heusler H; Zilly W
    Leber Magen Darm; 1980 Oct; 10(5):234-40. PubMed ID: 7464410
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of tuberculostatic agents on the response of serum growth hormone and immunoreactive insulin to intravenous tolbutamide, and on the half-life of tolbutamide.
    Syvälahti E; Pihlajamäki K; Iisalo E
    Int J Clin Pharmacol Biopharm; 1976 Mar; 13(2):83-9. PubMed ID: 1254383
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sulfamethizole-induced inhibition of diphenlhydantoin, tolbutamide, and warfarin metabolism.
    Lumholtz B; Siersbaek-Nielsen K; Skovsted L; Kampmann J; Hansen JM
    Clin Pharmacol Ther; 1975 Jun; 17(6):731-4. PubMed ID: 1139863
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hexobarbital disposition in compensated and decompensated cirrhosis of the liver.
    Zilly W; Breimer DD; Richter E
    Clin Pharmacol Ther; 1978 May; 23(5):525-34. PubMed ID: 639426
    [No Abstract]   [Full Text] [Related]  

  • 27. Comparison of rifampicin with phenobarbitone for treatment of pruritus in biliary cirrhosis.
    Bachs L; Parés A; Elena M; Piera C; Rodés J
    Lancet; 1989 Mar; 1(8638):574-6. PubMed ID: 2564110
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Kinetics of rifampicin and isoniazid administered alone and in combination to normal subjects and patients with liver disease.
    Acocella G; Bonollo L; Garimoldi M; Mainardi M; Tenconi LT; Nicolis FB
    Gut; 1972 Jan; 13(1):47-53. PubMed ID: 5060669
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enhanced plasma binding of propranolol and oxprenolol and induction of hexobarbital and antipyrine metabolism by rifampicin treatment in the dog.
    Belpaire FM; Rosseel MT; De Rick A
    Arch Int Pharmacodyn Ther; 1982 Oct; 259(2):303-4. PubMed ID: 7181586
    [No Abstract]   [Full Text] [Related]  

  • 30. Effect of rifampicin in the treatment of pruritus in hepatic cholestasis.
    Gregorio GV; Ball CS; Mowat AP; Mieli-Vergani G
    Arch Dis Child; 1993 Jul; 69(1):141-3. PubMed ID: 8024298
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential induction of antipyrine metabolism by rifampicin.
    Toverud EL; Boobis AR; Brodie MJ; Murray S; Bennett PN; Whitmarsh V; Davies DS
    Eur J Clin Pharmacol; 1981; 21(2):155-60. PubMed ID: 7341283
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influence of the rate of hepatic portal vein infusion on hexobarbital pharmacokinetics in the rat.
    Joeres RP; Vermeulen NP; Breimer DD
    Pharmacology; 1988; 36(3):210-6. PubMed ID: 3368506
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Deviation in cortisol metabolism induced by rifampicin. Therapeutic consequences in adrenal failure (author's transl)].
    Bouchard P; Kuttenn F; Nahoul K; Mavier P; Schaison G; Mauvais-Jarvis P
    Nouv Presse Med; 1979 May; 8(20):1651-4. PubMed ID: 471734
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hexobarbitone disposition at different stages of intensive care treatment.
    Rietbrock I; Lazarus G; Richter E; Breimer DD
    Br J Anaesth; 1981 Mar; 53(3):283-93. PubMed ID: 7470363
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cytoprotective properties of rifampicin are related to the regulation of detoxification system and bile acid transporter expression during hepatocellular injury induced by hydrophobic bile acids.
    González R; Cruz A; Ferrín G; López-Cillero P; Briceño J; Gómez MA; Rufián S; Padillo J; De la Mata M; Marin JJ; Muntané J
    J Hepatobiliary Pancreat Sci; 2011 Sep; 18(5):740-50. PubMed ID: 21526375
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Symposion B: Experimental cholestasis--in vitro metabolism and in vivo metabolic clearance of hexobarbital in rats with ANIT-cholestasis].
    Richter E; Brachtel D; Gallenkamp H; Zilly W
    Verh Dtsch Ges Inn Med; 1976; 82 Pt 1():269-71. PubMed ID: 829378
    [No Abstract]   [Full Text] [Related]  

  • 37. Pharmocokinetics of hexobarbital in man after intravenous infusion.
    Breimer DD; Honhoff C; Zilly W; Richter E; van Rossum JM
    J Pharmacokinet Biopharm; 1975 Feb; 3(1):1-11. PubMed ID: 1127574
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Effect of rifampicin on the pharmacokinetics of tolbutamide in healthy subjects].
    Zilly W; Bopp E; Bürkl B; Richter E
    Verh Dtsch Ges Inn Med; 1974; 80():1538-40. PubMed ID: 4454477
    [No Abstract]   [Full Text] [Related]  

  • 39. Lack of efficacy of cimetidine and ranitidine as inhibitors of tolbutamide metabolism.
    Adebayo GI; Coker HA
    Eur J Clin Pharmacol; 1988; 34(6):653-6. PubMed ID: 3169118
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differential effects of hepatic cirrhosis on the intrinsic clearances of sorafenib and imatinib by CYPs in human liver.
    Murray M; Gillani TB; Ghassabian S; Edwards RJ; Rawling T
    Eur J Pharm Sci; 2018 Mar; 114():55-63. PubMed ID: 29223619
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.